Skip to main content

Want a detailed portfolio tracker?

NGNE
NASDAQ
$37.34

Neoleukin Therapeutics Inc (NGNE)

Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders, addressing significant unmet medical needs in the field of genetic medicine. The company boasts a promising and proprietary pipeline, showcasing its commitment to harnessing cutting-edge technologies for transformative treatment solutions. With a seasoned leadership team guiding its strategic direction, Neurogene is poised to make substantial contributions to the advancement of genetic therapies, ultimately enhancing the quality of life for patients and their families impacted by these challenging conditions. As Neurogene progresses through critical clinical development phases, it stands as a key player in the evolving landscape of genetic therapeutics.
Website: https://www.neurogene.com
Sector:
Healthcare
Industry:
Biotechnology
68 analysts
Buy
Target: $81.71 (+118.83%)

Market Cap

$616M

Free Cash Flow Yield

-13.51%

Beta (5Y)

1.88

Price Chart

Valuation
Market Cap$616M
P/S583.60
P/B3.28
Profitability
Gross Profit (TTM)-$82M
EBITDA-$108M
EPS-$6.54
Financial Health
Free Cash Flow Yield-13.51%
Growth & Risk
EPS 5Y CAGR+11.24%
FCF 5Y CAGR+19.12%
Beta (5Y)1.88
Sharpe Ratio0.97